

These amendments add no new matter. The specification contains support for these amendments as follows: Figs. 2A and 2B, for example, shows an antibody (V<sub>L</sub>/V<sub>H</sub>) attached to the amino terminus of a therapeutic agent (PE38). Page 18 of the specification states that "The anti-CD22 antibody . . . can be linked to *Pseudomonas* exotoxin through the PE carboxyl terminus, the PE amino terminus, through an interior amino acid residue of PE such as cysteine, or any combination thereof."

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



John Storella  
Reg. No. 32,944

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200  
Fax: (415) 576-0300  
JRS  
SF 1069261 v1